Growth Metrics

Emergent BioSolutions (EBS) Equity Ratio (2016 - 2026)

Emergent BioSolutions has reported Equity Ratio over the past 17 years, most recently at 0.4 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 2.22% year-over-year to 0.4; the TTM value through Mar 2026 reached 0.4, up 2.22%, while the annual FY2025 figure was 0.4, 14.08% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.4 at Emergent BioSolutions, roughly flat from 0.4 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.56 in Q1 2022 and troughed at 0.26 in Q2 2024.
  • A 5-year average of 0.41 and a median of 0.4 in 2026 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: tumbled 41.93% in 2024 and later soared 48.25% in 2025.
  • Year by year, Equity Ratio stood at 0.44 in 2022, then decreased by 18.74% to 0.36 in 2023, then dropped by 2.45% to 0.35 in 2024, then rose by 14.08% to 0.4 in 2025, then dropped by 0.04% to 0.4 in 2026.
  • Business Quant data shows Equity Ratio for EBS at 0.4 in Q1 2026, 0.4 in Q4 2025, and 0.4 in Q3 2025.